8-K: Delcath Systems Reports Increased Treatment Site Guidance Following Successful HEPZATO KIT Launch

Delcath Systems announced positive fourth quarter and full year 2023 results, highlighted by the successful commercial launch of HEPZATO KIT and an increase in 2024 treatment site activation guidance.

Summary

• Delcath Systems reported its fourth quarter and full year 2023 financial results, showing a revenue of approximately $0.5 million for the quarter and $2.1 million for the year.
• The company's cash, cash equivalents, and investments totaled $32.5 million as of December 31, 2023.
• A $7.0 million private placement financing was completed on March 19, 2024, strengthening the company's balance sheet.
• Research and development expenses were $4.7 million for the quarter and $17.5 million for the year, while selling, general, and administrative expenses increased to $7.0 million and $22.1 million, respectively.
• Delcath has increased its 2024 treatment site activation guidance to 20 sites, up from the previous 15.
• The company received a permanent J-code (J9248) and transitional pass-through payment status for HEPZATO, effective April 1, 2024.
• The first commercial use of HEPZATO KIT for metastatic uveal melanoma (mUM) was announced at Moffitt Cancer Center.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments such as the successful launch of HEPZATO KIT, increased treatment site guidance, and a capital raise, the company also reported a net loss and decreased revenue compared to the previous year. The sentiment is cautiously optimistic.

Positives

• The successful commercial launch of HEPZATO KIT is a major milestone for the company.
• The increase in treatment site activation guidance to 20 sites indicates strong demand and adoption of the product.
• Securing a permanent J-code and transitional pass-through payment status for HEPZATO will improve reimbursement and patient access.
• The $7.0 million private placement strengthens the company's financial position.
• The appointment of Martha S. Rook as COO brings significant industry experience to the leadership team.
• Positive clinical study results support the efficacy and safety of Delcath's treatment methods.

Negatives

• Total revenue for the quarter and year decreased compared to the same periods in the prior year.
• The company experienced a net loss of $11.136 million for the quarter and $47.678 million for the year.
• Selling, general, and administrative expenses increased significantly due to commercial launch activities.

Risks

• The company's ability to successfully commercialize HEPZATO KIT is subject to uncertainties.
• Managing the HEPZATO KIT supply chain and securing adequate supply of critical components is crucial.
• Successful FDA inspections of the company's facilities and those of its third-party suppliers are necessary.
• The company's ability to obtain reimbursement for HEPZATO KIT is not guaranteed.
• Entering into necessary purchase and sale agreements with users of HEPZATO KIT is essential for revenue generation.

Future Outlook

The company expects to activate a total of 20 treatment sites by the end of 2024 and is focused on the successful commercialization of HEPZATO KIT.

Management Comments

• We have made tremendous progress since the January launch of HEPZATO KIT in the US, said Gerard Michel, Delcaths Chief Executive Officer.
• We have successfully secured a product specific J-Code and, with over 90 preceptorships completed by healthcare professionals across approximately 20 institutions in the US, are on track to train and activate 20 sites by year end.
• Furthermore, we have strengthened our balance sheet with additional investment from senior management and existing investors.
• I am proud of the teams success in providing access to a new treatment for patients suffering from metastatic uveal melanoma.

Industry Context

This announcement reflects the growing focus on targeted therapies for liver cancers and the increasing adoption of interventional oncology procedures. The successful launch of HEPZATO KIT positions Delcath as a key player in this space.

Comparison to Industry Standards

• Delcath's focus on liver-directed therapies aligns with the industry trend towards more precise cancer treatments, similar to companies like Sirtex Medical (now owned by Varian) which focuses on SIRT.
• The reported median overall survival of 516 days for PHP in the retrospective study is a positive result, comparing favorably to other liver cancer treatments.
• The company's efforts to secure a J-code for HEPZATO are crucial for reimbursement, similar to how other medical device and drug companies navigate the complex healthcare payment landscape.
• The increase in treatment site activation guidance to 20 sites is a positive sign of market adoption, which is a key metric for companies in the medical device and pharmaceutical sectors.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the financial results and the company's future performance.
• Employees will be affected by the company's growth and commercialization efforts.
• Patients will benefit from the availability of HEPZATO KIT as a treatment option.
• Healthcare providers will be impacted by the training and activation of new treatment sites.
• Suppliers will be impacted by the company's supply chain management.

Next Steps

• The company will continue to focus on activating 20 treatment sites by the end of 2024.
• Delcath will work to ensure the successful commercialization of HEPZATO KIT.
• The company will manage the HEPZATO KIT supply chain and secure adequate supply of critical components.
• Delcath will continue to seek reimbursement for HEPZATO KIT.

Key Dates

Keywords

HEPZATO KIT, metastatic uveal melanoma, liver cancer, melphalan, hepatic perfusion, CHEMOSAT, J-code, treatment sites, oncology, interventional oncology